To address this knowledge gap, the present study aims to elucidate the key molecular regulatory networks of CHI3L1 in RA and evaluate its potential clinical utility as a biomarker for diagnosis and disease activity assessment. Here, CHI3L1 is linked to rheumatoid arthritis.